Number of patients / group number |
|
60 |
1 |
2511 |
2 |
789 |
3 |
349 |
4 |
|
|
|
Form of results presentation (count/average; Sd/%) |
|
Count
/ average |
%/Sd |
Count / average |
%/Sd |
Count / average |
%/Sd |
Count / average |
%/Sd |
|
|
|
Patient’s age during TLE |
Aver±Sd |
68,95 |
12,56 |
64,77 |
16,38 |
69,51 |
13,23 |
66,38 |
14,27 |
0,05 |
0,45 |
0,19 |
Patient’s age during first system implantation |
Aver±Sd |
62,00 |
13,10 |
55,93 |
17,98 |
61,87 |
14,14 |
68,61 |
15,65 |
0,01 |
0,94 |
<0,01 |
Sex (% of male patients) (%) |
n (%) |
33 |
55,00% |
1452 |
57,83% |
564 |
71,48% |
243 |
69,63% |
0,64 |
<0,01 |
0,03 |
Underlaying heart disease: IHD, MI |
n (%) |
35 |
58,33% |
1410 |
56,15% |
442 |
56,02% |
177 |
50,72% |
0,71 |
0,70 |
<0,01 |
NYHA III & IV |
n (%) |
4 |
6,67% |
354 |
14,10% |
104 |
13,18% |
99 |
28,37% |
0,10 |
0,14 |
0,18 |
Congestive heart failure (symptomatic presently) |
n (%) |
5 |
8,33% |
488 |
19,43% |
118 |
14,96% |
84 |
24,07% |
0,04 |
0,15 |
0,58 |
LVEF average (%) |
Aver±Sd |
49,73 |
14,13% |
49,99 |
15,46% |
48,520 |
14,64% |
47,37 |
15,45% |
0,90 |
0,54 |
0,26 |
LVEF significantly limited / decreased / reduced
(<30%) |
n (%) |
7 |
11,67% |
304 |
12,1% |
104 |
13,18% |
55 |
15,76% |
0,90 |
0,71 |
0,41 |
Renal failure (any) |
n (%) |
12 |
20,00% |
465 |
18,52% |
181 |
22,94% |
133 |
38,11% |
0,76 |
0,60 |
0,51 |
Diabetes (any) |
n (%) |
7 |
11,67% |
452 |
18,00% |
179 |
22,69% |
101 |
28,94% |
0,21 |
0,05 |
0,81 |
Malignancy in history |
n (%) |
4 |
6,67% |
160 |
6,37% |
48 |
6,08% |
26 |
7,45% |
0,91 |
0,84 |
0,17 |
Treatment with steroids in history |
n (%) |
0 |
0,00% |
29 |
1,15% |
18 |
2,28% |
15 |
4,30% |
0,40 |
0,23 |
0,26 |
Permanent AF presence |
n (%) |
12 |
20,00% |
536 |
21,35% |
206 |
26,11% |
89 |
25,50% |
0,80 |
0,27 |
0,05 |
Mechanical valve presence |
n (%) |
1 |
1,67% |
132 |
5,26% |
35 |
4,44% |
15 |
4,30% |
0,21 |
0,28 |
0,88 |
Long-term anticoagulation was necessary |
n (%) |
26 |
43,33% |
982 |
39,11% |
290 |
36,76% |
146 |
41,83% |
0,49 |
0,29 |
0,29 |
Long-term antiplatelet therapy in recent history |
n (%) |
29 |
48,33% |
1055 |
42,02% |
342 |
43,35% |
150 |
42,98% |
0,31 |
0,46 |
<0,01 |
CHA2DS2–VASc scale -
number of points |
Aver±Sd |
3,20 |
0,01 |
2,90 |
1,73 |
3,19 |
1,67 |
3,17 |
1,75 |
0,18 |
0,96 |
0,90 |
HAS-BLED scale - number of points |
Aver±Sd |
1,73 |
0,01 |
1,34 |
1,03 |
1,62 |
1,02 |
1,64 |
1,16 |
<0,01 |
<0,01 |
<0,01 |
Charlson’s co-morbidity
index - number of points |
Aver±Sd |
4,28 |
3,05 |
4,48 |
3,62 |
5,13 |
3,63 |
5,56 |
4,02 |
0,67 |
0,08 |
0,02 |
BMI |
Aver±Sd |
27,65 |
4,66 |
27,95 |
5,74 |
27,72 |
3,87 |
27,65 |
4,48 |
0,69 |
0,08 |
1,00 |
CRP level |
Aver±Sd |
15,56 |
34,90 |
10,67 |
24,65 |
29,09 |
43,45 |
75,40 |
77,84 |
0,13 |
0,02 |
<0,01 |
WBC (thousands) |
Aver±Sd |
8,22 |
2,82 |
7,73 |
3,41 |
8,37 |
3,33 |
11,08 |
6,25 |
0,27 |
0,73 |
<0,01 |
Haemoglobin |
Aver±Sd |
13,03 |
1,79 |
13,28 |
1,76 |
12,68 |
1,88 |
11,26 |
2,14 |
0,28 |
0,16 |
<0,01 |